Global Patent Index - EP 1277754 A4

EP 1277754 A4 2003-06-04 - IMIDAZOPYRIDINE DERIVATIVES

Title (en)

IMIDAZOPYRIDINE DERIVATIVES

Title (de)

IMIDAZOPYRIDIN-DERIVATE

Title (fr)

DERIVES D'IMIDAZOPYRIDINE

Publication

EP 1277754 A4 (EN)

Application

EP 01925980 A

Priority

  • JP 0103649 W
  • JP 2000128295 A

Abstract (en)

[origin: EP1277754A1] The present invention relates to novel compounds having a phosphatidylinositol 3 kinase (PI3K) inhibiting activity which are useful as medicaments, more particularly as antitumor agent. Novel 3-(imidazoÄ1,2-aÜpyridin-3-yl) derivatives or salts thereof exhibit an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity, and are thus useful as medicaments, especially as PI3K inhibitors and antitumor agents.

IPC 1-7 (main, further and additional classification)

C07D 471/04; A61K 31/437; A61K 31/444; A61K 31/4545; A61K 31/4709; A61K 31/496; A61K 31/5025; A61K 31/5377; A61P 35/00; A61P 43/00; C07D 487/04

IPC 8 full level (invention and additional information)

A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)

CPC (invention and additional information)

C07D 471/04 (2013.01); C07D 487/04 (2013.01)

Citation (search report)

  • [XA] EP 0430385 A2 19910605 - SCHERING AG [DE]
  • [X] WO 9634866 A1 19961107 - FUJISAWA PHARMACEUTICAL CO [JP], et al
  • [E] WO 0138326 A2 20010531 - MERCK SHARP & DOHME [GB], et al
  • [E] WO 0164674 A1 20010907 - JANSSEN PHARMACEUTICA NV [BE], et al
  • [E] WO 0212236 A1 20020214 - LOESEL PETER [DE], et al
  • [E] WO 0234748 A1 20020502 - SANKYO CO [JP], et al
  • [A] PATENT ABSTRACTS OF JAPAN vol. 015, no. 248 (C - 0843) 25 June 1991 (1991-06-25)
  • [A] VLAHOS C J ET AL: "A SPECIFIC INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE, 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE (LY294002)", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 269, no. 7, 18 February 1994 (1994-02-18), pages 5241 - 5248, XP002023636, ISSN: 0021-9258
  • [A] DODGE J A ET AL: "17beta-hydroxywortmannin: a potent inhibitor or bone resorption and phosphatidylinositol-3-kinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 5, no. 15, 3 August 1995 (1995-08-03), pages 1713 - 1718, XP004135413, ISSN: 0960-894X
  • See also references of WO 0183481A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

EPO simple patent family

EP 1277754 A1 20030122; EP 1277754 A4 20030604; EP 1277754 B1 20050727; EP 1277754 B8 20050928; AT 300540 T 20050815; AU 5260901 A 20011112; CA 2407573 A1 20011108; CA 2407573 C 20110913; CN 1173975 C 20041103; CN 1308327 C 20070404; CN 1426413 A 20030625; CN 1600783 A 20050330; DE 60112272 D1 20050901; DE 60112272 T2 20060524; DK 1277754 T3 20051114; ES 2244613 T3 20051216; JP 3729343 B2 20051221; KR 100830859 B1 20080521; KR 20030014206 A 20030215; WO 0183481 A1 20011108

INPADOC legal status


2018-04-30 [PGFP GB] POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE

- Ref Country Code: GB

- Payment date: 20180329

- Year of fee payment: 18

2018-04-30 [PGFP NL] POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE

- Ref Country Code: NL

- Payment date: 20180314

- Year of fee payment: 18

2018-03-15 [REG FR PLFP] FEE PAYMENT

- Year of fee payment: 18

2017-08-31 [PGFP SE] POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE

- Ref Country Code: SE

- Payment date: 20170411

- Year of fee payment: 17

2017-08-31 [PGFP IT] POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE

- Ref Country Code: IT

- Payment date: 20170420

- Year of fee payment: 17

2017-07-31 [PGFP DE] POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE

- Ref Country Code: DE

- Payment date: 20170420

- Year of fee payment: 17

2017-07-31 [PGFP IE] POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE

- Ref Country Code: IE

- Payment date: 20170410

- Year of fee payment: 17

2017-07-31 [PGFP CH] POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE

- Ref Country Code: CH

- Payment date: 20170412

- Year of fee payment: 17

2017-07-31 [PGFP DK] POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE

- Ref Country Code: DK

- Payment date: 20170411

- Year of fee payment: 17

2017-06-30 [PGFP ES] POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE

- Ref Country Code: ES

- Payment date: 20170316

- Year of fee payment: 17

2017-04-28 [PGFP FR] POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE

- Ref Country Code: FR

- Payment date: 20170313

- Year of fee payment: 17

2017-03-13 [REG FR PLFP] FEE PAYMENT

- Year of fee payment: 17

2016-03-09 [REG FR PLFP] FEE PAYMENT

- Year of fee payment: 16

2011-03-31 [REG CH PFA] NAME/FIRM CHANGED

- Owner name: IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED

- Free text: IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED#SARDINIA HOUSE, SARDINIA STREET#LONDON WC2A 3NL (GB) $ LUDWIG INSTITUTE FOR CANCER RESEARCH#605 THIRD AVENUE#NEW YORK, NEW YORK 10158 (US) $ ASTELLAS PHARMA INC.#3-11, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU#TOKYO 103-8411 (JP) -TRANSFER TO- IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED#SARDINIA HOUSE, SARDINIA STREET#LONDON WC2A 3NL (GB) $ LUDWIG INSTITUTE FOR CANCER RESEARCH#605 THIRD AVENUE#NEW YORK, NEW YORK 10158 (US) $ ASTELLAS PHARMA INC.#3-11, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU#TOKYO 103-8411 (JP)

2008-11-28 [PG25 CY] LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO

- Ref Country Code: CY

- Free text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

- Effective date: 20050727

2008-07-31 [PG25 LU] LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO

- Ref Country Code: LU

- Free text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

- Effective date: 20060426

2007-12-31 [BECN] BE: CHANGE OF HOLDER'S NAME

- Owner name: *ASTELLAS PHARMA INC.

- Effective date: 20050727

2007-12-31 [BECN] BE: CHANGE OF HOLDER'S NAME

- Owner name: *LUDWIG INSTITUTE FOR CANCER RESEARCH

- Effective date: 20050727

2007-12-31 [BECN] BE: CHANGE OF HOLDER'S NAME

- Owner name: *IMPERIAL CANCER RESEARCH TECHNOLOGY LTD

- Effective date: 20050727

2006-07-05 [26N] NO OPPOSITION FILED

- Effective date: 20060428

2006-05-05 [ET] FR: TRANSLATION FILED

2006-04-30 [PG25 MC] LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO

- Ref Country Code: MC

- Free text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

- Effective date: 20060430

2005-12-27 [PG25 PT] LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO

- Ref Country Code: PT

- Free text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

- Effective date: 20051227

2005-12-16 [REG ES FG2A] DEFINITIVE PROTECTION

- Document: ES 2244613 T3

2005-11-15 [REG CH NV] NEW AGENT

- Representative's name: BOVARD AG PATENTANWAELTE

2005-11-14 [REG DK T3] TRANSLATION OF EP PATENT

2005-11-01 [NLT2] NL: MODIFICATIONS (OF NAMES), TAKEN FROM THE EUROPEAN PATENT PATENT BULLETIN

- Owner name: ASTELLAS PHARMA INC. EN LUDWIG INSTITUTE FOR CANCE

- Effective date: 20050831

2005-10-27 [PG25 GR] LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO

- Ref Country Code: GR

- Free text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

- Effective date: 20051027

2005-10-18 [REG SE TRGR] TRANSLATION OF GRANTED EP PATENT

2005-09-01 [REF] CORRESPONDS TO:

- Document: DE 60112272 P 20050901

2005-08-31 [RAP2] TRANSFER OF RIGHTS OF AN EP GRANTED PATENT

- Owner name: ASTELLAS PHARMA INC.

2005-08-31 [RAP2] TRANSFER OF RIGHTS OF AN EP GRANTED PATENT

- Owner name: LUDWIG INSTITUTE FOR CANCER RESEARCH

2005-08-31 [RAP2] TRANSFER OF RIGHTS OF AN EP GRANTED PATENT

- Owner name: IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED

2005-08-24 [REG IE FG4D] EUROPEAN PATENTS GRANTED DESIGNATING IRELAND

2005-07-29 [REG CH EP] ENTRY IN THE NATIONAL PHASE

2005-07-27 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: B1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

2005-07-27 [REG GB FG4D] EUROPEAN PATENT GRANTED

2005-07-27 [PG25 AT] LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO

- Ref Country Code: AT

- Free text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

- Effective date: 20050727

2005-07-27 [PG25 BE] LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO

- Ref Country Code: BE

- Free text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

- Effective date: 20050727

2005-07-27 [PG25 FI] LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO

- Ref Country Code: FI

- Free text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

- Effective date: 20050727

2005-07-27 [PG25 TR] LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO

- Ref Country Code: TR

- Free text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

- Effective date: 20050727

2003-09-03 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20030716

2003-06-04 [A4] DESPATCH OF SUPPLEMENTARY SEARCH REPORT

- Effective date: 20030425

2003-01-22 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20021021

2003-01-22 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

2003-01-22 [AX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO:

- Free text: AL;LT;LV;MK;RO;SI